Global Study: COVID-19 And Adenoviral Vaccines Tied To GBS Risk, Not MRNA Vaccines

Large-scale study in a population covering more than 230 million people sheds light on the relationship between Guillain-Barré syndrome after COVID-19 vaccines or SARS-CoV-2 infection.

Auckland, 29 May 2025 – A new multinational study analysing data from over 230 million people across 20 global sites highlights the relationship between SARS-CoV-2 infection, certain COVID-19 vaccines, and Guillain-Barré syndrome (GBS). This research reinforces the importance of continuous vaccine safety monitoring and highlights key differences in risk associated with different vaccine types.

GBS is a rare but serious neurological condition that can cause progressive limb weakness and eventual paralysis, with an annual incidence of 1 to 4 cases per 100,000 people worldwide. It has been linked to various infections, including Campylobacter jejuni, Zika virus, influenza, and SARS-CoV-2.

The study used advanced epidemiological methods and healthcare data from 20 sites within GVDN: seven sites from the African COVID-19 Vaccine Safety Surveillance (ACVaSS) system: Ethiopia, Ghana, Kenya, Malawi, Mali, Mozambique, and Nigeria; Argentina; New South Wales and Victoria in Australia; British Columbia and Ontario in Canada; Denmark; Finland; Indonesia; Republic of Korea; South Africa; and three Vaccine monitoring Collaboration for Europe (VAC4EU) sites: Catalonia and Valencia in Spain, and the United Kingdom.

People infected with SARS-CoV-2 were around three times more likely to develop Guillain-Barré syndrome (GBS) within six weeks of infection compared to other times, suggesting that infection with this virus increases the risk of GBS. An increased risk was also observed following adenoviral vector vaccines (AstraZeneca, Janssen/Johnson & Johnson), but not after mRNA vaccines (Pfizer-BioNTech, Moderna) or inactivated vaccines (Coronavac/Sinovac).

“If you are concerned about the risk of rare but serious side effects of vaccines such as GBS, you should know that receiving an mRNA COVID-19 vaccine does not appear to increase your risk, but infection with the virus does,” said Dr. Jeff Kwong, senior author for the study based at ICES and the University of Toronto in Canada. “This study reinforces what we have known for some time—the potential health risks from COVID-19 disease are greater than the risks following COVID-19 vaccination, which plays an important role in protecting us from serious risks posed by infection.”

“Understanding the relative risks of vaccination and infection is critical. This study reinforces that while certain vaccines may carry small risks, SARS-CoV-2 infection itself presents a much greater threat to neurological health,” said Dr. Sharifa Nasreen, Assistant Professor at SUNY Downstate Health Sciences University, USA.

“Our findings emphasise that vaccine safety is not static—it is continuously studied and evaluated. The global research community remains committed to ensuring public confidence through ongoing safety monitoring and evidence-based guidance,” said Dr. Helen Petousis-Harris, GVDN Co-Director and Associate Professor at the University of Auckland.

GVDN collaborates with leading research institutions, policymakers, and vaccine organisations across six continents to create a comprehensive, evidence-based approach to vaccine safety and effectiveness. This large-scale study underscores the importance of vaccination as a tool for public health, not only in preventing severe disease but in reducing rare complications like GBS. Dr. Steve Black, GVDN Co-Director, stated, “GVDN has long been committed to rigorous and transparent vaccine safety research. The size and diversity of this study population, attained through multinational collaboration, is a testament to this. Our findings highlight the importance of continuous monitoring and real-world data to guide public health decisions.”

About Global Vaccine Data Network™ (GVDN®)

Global Vaccine Data Network (GVDN) brings together researchers across six continents to deliver independent, real-world data on vaccine safety and effectiveness, supporting evidence-based public health decisions.

Established in 2019, GVDN collaborates with renowned research institutions, policy-makers, and vaccine-related organisations to establish a harmonised and evidence-based approach to evaluating vaccine safety and effectiveness using data sourced from millions of individuals across six continents. GVDN is supported by the Global Coordinating Centre based at Auckland UniServices Limited, a not-for-profit, stand-alone company that provides support to researchers and is wholly owned by the Waipapa Taumata Rau, University of Auckland. Aiming to gain a comprehensive understanding of vaccine safety and effectiveness profiles, GVDN strives to create a safer immunisation landscape that empowers decision-making for the global community. For further information, visit globalvaccinedatanetwork.org.

Disclaimer

This news release summarises the key findings of the GVDN study to identify the association between the risk of Guillain-Barré Syndrome (GBS) and COVID-19 infection or vaccination. To view the full publication in Vaccine, visit doi.org/10.1016/j.vaccine.2025.127291. This project was supported by the Centers for Disease Control and Prevention (CDC) of the U.S. Department of Health and Human Services (HHS). The contents are those of the authors and do not necessarily represent the official views of, nor an endorsement by, CDC/HHS, or the U.S. Government.

© Scoop Media